Vaxcyte Inc (PCVX) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 2[2].
Trial NCT07284654[4] evaluates 31 valent pneumococcal conjugate vaccine in Pneumococcal Vaccines with a target enrollment of 4049 participants. Trial NCT07425392[5] evaluates 31-valent pneumococcal conjugate vaccine in Pneumococcal Vaccines with a target enrollment of 720 participants. Trial NCT07365826[6] evaluates 31-valent pneumococcal conjugate vaccine in Pneumococcal Vaccines with a target enrollment of 1390 participants.
PCVX has 3 Form 4 insider filings recorded at the SEC in the past 30 days[7].